Sort   by:  
 Page size 
UnknownPan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers.
Not available
S-EPMC7196502 | biostudies-literature
UnknownAnti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
Not available
S-EPMC9931830 | biostudies-literature
UnknownA CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.
Not available
S-EPMC7142219 | biostudies-literature
UnknownVemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Not available
S-EPMC5844839 | biostudies-literature
UnknownPRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
Not available
S-EPMC6236466 | biostudies-literature
UnknownBRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.
Not available
S-EPMC6286161 | biostudies-literature
UnknownEstimating One-Year Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study Using Electronic Medical Record Data From the State of Maine.
Not available
S-EPMC5550735 | biostudies-literature
UnknownIdentification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma.
Not available
S-EPMC12214876 | biostudies-literature
UnknownUtilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups.
Not available
S-EPMC12261794 | biostudies-literature
UnknownPersonalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of a pilot study.
Not available
S-EPMC9896212 | biostudies-literature
Sort   by:  
 Page size